About Melo

Melo • rhe • ostosis

What is Melo?

Melorheostosis is a rare and progressive bone disorder characterized by significant thickening of the cortical bone.  It affects both bone and soft tissue growth and development. On x-rays, the appearance of melorheostosis has been likened to flowing, melted candle wax.

Crowd of multi generational people having fun together and hugging each other outdoors
Doctor using a laptop consulting patient in bright clinic office

Our Mission

The Melorheostosis Association is a 501(c)(3) non-profit organization dedicated to finding the causes, treatments, and cures for melorheostosis. We focus on promoting greater awareness and understanding of this progressive disease and its manifestations through education, research, communication, and advocacy efforts on behalf of those affected by it as well as those dedicated to alleviating it.

About the Board

The Association is registered as a 501(c)(3) and is run by an all-volunteer board including a president, secretary, treasurer, and chairperson/founder. Board members plan conferences and events, foster communication between researchers and the patient community, and oversee fundraising efforts to support the patient community and ongoing research. A medical panel is in place to support the Association with best practices,  research efforts, and patient advocacy in the rare disease space.

Melo Through the Years

Learn more about the major milestones throughout the history of Melorheostosis, the Association, and patient research advancements.

1922

Melorheostosis first identified by Leri and Joanny in France.

2001

Melorheostosis Association established by patients and parents looking to support the advancement of research and patient connection.

2003

First Melorheostosis Association conference held—kicking off biennial conferences for patients, supporters, researchers, and medical professionals.

2015

National Institutes of Health launches a natural history study and begins recruiting patients.

2018

Somatic mutations in MAP2K1 identified as one cause of melorheostosis—other genes include KRAS, LEMD3, and SMAD3.

20??

Our next milestone: patients gain access to treatments to stop the progression of Melorheostosis.

Who We Can Help

The Melorheostosis Association was formed by patients and supporters to bring the patient community together from across the world while focusing on research and advocacy to identify causes and treatments for those affected by melorheostosis.

Patient Support

We know life with a rare disease comes with challenges. We’re here to provide trusted resources, community connection, guidance for managing your care, and research opportunities.

Medical Professionals

Supporting patients with their rare disease journey is critical. We are here to provide the most recent research, resources, and connections to ongoing research to better support your patients.

Pharmaceutical Partners

Rare disease research relies on collaboration with patient communities, data, and patient engagement. We want to continue accelerating scientific breakthroughs with a focus on treatments that slow or stop the progression of melorheostosis for our patients. We are on a mission to transform the lives of those living with melorheostosis.

Upcoming Conference

Stay tuned for more details on our 15th International Conference in 2027. We look forward to bringing patients and supporters together with researchers and doctors as we learn from the latest research and champion the work towards treatments. Sign up to stay connected and receive conference announcements.

Group of people sitting in a circle talking